85-1453-35　［取扱停止］Transglutaminase, Tissue, Recombinant, Human (tTG) 5ug　T8259-98

特徴

• Celiac disease is an enteropathy that is characterized by intestinal lesions of variable severity. Tissue-type transglutaminase (tTG) is believed to be the predominant autoantigen for celiac disease and the corresponding autoantibodies show higher sensitivity and specificity than anti-gliadin antibodies. Highly pure recombinant human tTG is now available to replace the traditionally used tTG fraction from guinea pig. Tissue-type transglutaminase antigens have been specifically modified for improved handling: exchange of an active site amino acid eliminates the protein cross-linking activity of the enzyme, while maintaining the native three-dimensional structure and the enzyme's secondary GTPase activity. This engineering assures reproducible properties of the antigen preparations through the absence of variable and ill-defined covalent aggregates of tTG antigen and host cell proteins.
• Recombinant Human Tissue Transglutaminase produced in SF9 is a glycosylated, polypeptide chain having a molecular mass of 78.02kD. rHutTG is expressed with a -6xHis tag and purified by proprietary chromatographic techniques. By point mutation of the active center the catalytic transglutaminase activity has been eliminated, resulting in increased stability during storage and coating.
• Applications:Suitable for use in Western Blot with monoclonal anti-hexa-His-tag antibody and standard ELISA (checker-board analysis of positive/negative sera panels, immuno-dot test). Also suitable for biotinylation and iodination. Other applications not tested.
• Recommended Dilutions:ELISA: 0.6-1.4ug/ml (depending on the type of plate and coating buffer). Optimal dilutions to be determined by the researcher.
• Specificity:Binds IgG-type human auto-antibodies.
• Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.